Key Points
HBV/HCV coinfection enhanced fibrogenesis compared with HBV or HCV monoinfection.
HBV, HCV, and HBV/HCV induced liver fibrogenesis through the TGF-β1–OCT4/Nanog pathway.
Visual Abstract
Abstract
Hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection accelerates liver fibrosis progression compared with HBV or HCV monoinfection. Octamer binding transcription factor 4 (OCT4) and Nanog are direct targets of the profibrogenic TGF-β1 signaling cascade. We leveraged a coculture model to monitor the effects of HBV and HCV coinfection on fibrogenesis in both sodium taurocholate cotransporting polypeptide–transfected Huh7.5.1 hepatoma cells and LX2 hepatic stellate cells (HSCs). We used CRISPR-Cas9 to knock out OCT4 and Nanog to evaluate their effects on HBV-, HCV-, or TGF-β1–induced liver fibrogenesis. HBV/HCV coinfection and HBx, HBV preS2, HCV Core, and HCV NS2/3 overexpression increased TGF-β1 mRNA levels in sodium taurocholate cotransporting polypeptide–Huh7.5.1 cells compared with controls. HBV/HCV coinfection further enhanced profibrogenic gene expression relative to HBV or HCV monoinfection. Coculture of HBV and HCV monoinfected or HBV/HCV coinfected hepatocytes with LX2 cells significantly increased profibrotic gene expression and LX2 cell invasion and migration. OCT4 and Nanog guide RNA independently suppressed HBV-, HCV-, HBV/HCV-, and TGF-β1–induced α-SMA, TIMP-1, and Col1A1 expression and reduced Huh7.5.1, LX2, primary hepatocyte, and primary human HSC migratory capacity. OCT4/Nanog protein expression also correlated positively with fibrosis stage in liver biopsies from patients with chronic HBV or HCV infection. In conclusion, HBV and HCV independently and cooperatively promote liver fibrogenesis through a TGF-β1–induced OCT4/Nanog-dependent pathway.
Footnotes
This work was supported by grants from Natural Science Foundation of China (NSFC 82102383 to X.D., NSFC 81871661 to W. Lin, and NSFC 81770591 to Chuanlong Zhu), the Fundamental Research Funds for the Central Universities of China (WK9110000048 to W. Li), Natural Science Foundation of Anhui Province (Grant 1908085MH242), Sichuan Provincial Science and Technology Department (Grant 2019YJ0281), Key Project Foundation of Anhui Province, China (Grant S202104j07020097 to W. Li), Project Foundation of Academic Leader Anhui Province, China (Grant 2018H178 to W. Li), a project supported by Hainan Province Clinical Medical Center (to W. Li), U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (Grant R01AI155140 to R.T.C. and W. Lin), and Foundation for the National Institutes of Health (Grants AI069939, AI082630, DK098079, and DK108370 to R.T.C.).
W. Li., X.D., Chuanlong Zhu, R.T.C., and W. Lin designed and directed the project. W. Li, X.D., Chuanlong Zhu, X.L., and Z.T. performed experiments and analyzed data. X.L., A.J.J., M.X., Z.T., Q.S., D.C., Chuanwu Zhu, T.S., Z.C., A.J.K., J.A.H., E.A.S., and S.S. provided reagents and advice. W. Li., X.D., A.J.J., A.J.K., J.A.H., R.T.C., and W. Lin wrote and edited the manuscript with comments from all authors.
The online version of this article contains supplemental material.
Abbreviations used in this article
- Dac
- daclatasvir
- ECM
- extracellular matrix
- ETV
- entecavir
- gRNA
- guide RNA
- HBV
- hepatitis B virus
- HBVvp
- purified HBV particle
- HCC
- hepatocellular carcinoma
- HCV
- hepatitis C virus
- HCVvp
- purified HCV particle
- HSC
- hepatic stellate cell
- NTCP
- sodium taurocholate cotransporting polypeptide
- OCT4
- octamer binding transcription factor 4
- PHH
- primary human hepatocyte
- pHSC
- primary human hepatic stellate cell
- qPCR
- quantitative PCR
- Received December 29, 2020.
- Accepted November 13, 2021.
- Copyright © 2022 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.